Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ketamine intranasal - Seelos Therapeutics

Next Previous
X
Search
Drug Profile

Ketamine intranasal - Seelos Therapeutics

Alternative Names: Ereska; IN Ketamine; Intranasal ketamine; Intranasal racemic ketamine; PMI-100; PMI-150; SLS-002; TUR-002

Latest Information Update: 02 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Javelin Pharmaceuticals
  • Developer Seelos Therapeutics; US Army Medical Research and Development Command
  • Class Amines; Analgesics; Antidepressants; Antihyperglycaemics; Antiparkinsonians; Anxiolytics; Behavioural disorder therapies; Chlorobenzenes; Cyclohexanes; General anaesthetics; Ketones; Mood stabilisers; Neuroprotectants; Neuropsychotherapeutics; Obesity therapies; Small molecules
  • Mechanism of Action AMPA receptor agonists; Dopamine receptor agonists; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Post-traumatic stress disorders; Suicidal ideation
  • Discontinued Acute pain; Cancer pain

Most Recent Events

  • 24 Sep 2024 Seelos Therapeutics signs Material Transfer Agreement United States Army Medical Research and Materiel Command to evaluate its potential for treatment of post-traumatic stress disorder
  • 22 Jan 2024 Seelos Therapeutics announces the receipt of minutes from its end of phase II meeting with the US FDA highlighting modification of primary and secondary endpoints for phase III development
  • 22 Jan 2024 Seelos Therapeutics plans a phase III trial for Suicidal ideation in patients with Major depressive disorder in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top